Metagenomi Therapeutics, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 21 →InsidersNo open-market buys. 4 insiders sold $27,961, 0 of 10 sales on a 10b5-1 plan.→HoldersVanguard 2.9%Renaissance Technologies 2.0%Catalio 1.4%→PeersClosest companies: DTIL, NTLA, BEAM→
From the filings
Figures
- Revenue
- $22.3Mlast 12 months
- Net income
- −$93.5Mlast 12 months
- Operating cash flow
- −$87.2Mlast 12 months
- Cash and equivalents
- $39.0Mat the last balance sheet
- Shares outstanding
- 37.8M shareson issue